Abstract
Daily low‐dose aspirin showed a consistent lack of benefit on rates of Alzheimer's disease, mild cognitive impairment, and cognitive decline in a placebo‐controlled trial involving healthy older adults. The results follow earlier findings of no benefit of aspirin in prolonging disability‐free survival or decreasing the risk of incident dementia in the same study population.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call